Mirabegron for overactive bladder: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) Mirabegron has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee.